Accordingly, IL-17 induces an inflammatory tissue response and is elevated in patients with Salmonellosis [30] to suppress invasion of the organism to enteric mucosa by inducing AMPs (e.g., mBD3) [31], whereas IL-22 ameliorates intestinal inflammation [32] and mediates innate immunity to protection against Salmonella infection [33]. Here, IL17A is linked to salmonellosis.